SCHEDULE 13G: BlackRock Portfolio Management Discloses 5.1% Passive Stake in Stoke Therapeutics
Schedule 13G Filing
BlackRock Portfolio Management LLC has filed a Schedule 13G, revealing a 5.1% beneficial ownership stake in Stoke Therapeutics, Inc. as of March 31, 2025.
Summary
- BlackRock Portfolio Management LLC, a Delaware-organized entity, has filed a Schedule 13G with the SEC.
- The filing discloses beneficial ownership of common stock in Stoke Therapeutics, Inc. (CUSIP: 86150R107).
- As of March 31, 2025, BlackRock Portfolio Management LLC beneficially owns an aggregate of 2,743,502 shares of Stoke Therapeutics, Inc. common stock.
- This ownership represents 5.1% of the class of securities outstanding.
- The reporting person holds sole voting power over 2,609,626 shares and sole dispositive power over 2,743,502 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- BlackRock Portfolio Management LLC is classified as a parent holding company or control person, with several subsidiaries identified as potentially holding portions of the stake, including BlackRock Advisors, LLC and BlackRock Investment Management, LLC, one of which beneficially owns 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or forward-looking statements from the issuer.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of passive institutional ownership, common in the financial industry, and does not provide specific insights into Stoke Therapeutics' operational performance or the broader biotechnology sector beyond the fact that a major asset manager holds a stake.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership in Stoke Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 01/28/2025 | Date of execution for the Power of Attorney granted by BlackRock Portfolio Management LLC. |
| 03/31/2025 | Date of event which requires the filing of this statement, indicating the snapshot date for beneficial ownership. |
| 04/15/2025 | Date the Schedule 13G was signed by Spencer Fleming, Managing Director of BlackRock Portfolio Management LLC. |
Keywords
Stoke Therapeutics, BlackRock Portfolio Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, STOK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.